These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 30245117)

  • 1. Two novel SNPs in the promoter region of PKR gene in hepatitis C patients and their impact on disease outcome and response to treatment.
    El-Dahshan D; Bahy D; Wahid A; Ahmed AE; Hanora A
    Arab J Gastroenterol; 2018 Sep; 19(3):106-115. PubMed ID: 30245117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA protein kinase SNP at -226 CWahid A; Hamzawy MA; Khalifa MMA; Gad GFM; Bekhit A; Abdelwahab SF
    Immunol Invest; 2019 Apr; 48(3):211-221. PubMed ID: 30080984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection.
    Sarrazin C; Berg T; Weich V; Mueller T; Frey UH; Zeuzem S; Gerken G; Roggendorf M; Siffert W
    J Hepatol; 2005 Sep; 43(3):388-93. PubMed ID: 16019105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR.
    Knapp S; Yee LJ; Frodsham AJ; Hennig BJ; Hellier S; Zhang L; Wright M; Chiaramonte M; Graves M; Thomas HC; Hill AV; Thursz MR
    Genes Immun; 2003 Sep; 4(6):411-9. PubMed ID: 12944978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of IL12B gene rs 3212227 polymorphism on fibrosis, liver inflammation, and response to treatment in genotype 4 Egyptian hepatitis C patients.
    Youssef SS; Mostafa A; Saad A; Omran MH; El Zanaty T; Mohamed Seif S
    Dis Markers; 2013; 35(5):431-7. PubMed ID: 24223458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin.
    Abdelraheem WM; Hassuna NA; Abuloyoun SM; Abdel Ghany HM; Rizk HA; Abdelwahab SF
    Arch Virol; 2016 Sep; 161(9):2473-80. PubMed ID: 27352267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variants in the apoptosis gene BCL2L1 improve response to interferon-based treatment of hepatitis C virus genotype 3 infection.
    Clausen LN; Weis N; Ladelund S; Madsen L; Lunding S; Tarp B; Christensen PB; Krarup HB; Møller A; Gerstoft J; Clausen MR; Benfield T;
    Int J Mol Sci; 2015 Feb; 16(2):3213-25. PubMed ID: 25648321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection.
    Ali FT; Ali MA; Elgizawy MM; Elsawy AM
    Gut Liver; 2015 Jul; 9(4):516-24. PubMed ID: 25717047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Interleukin 28B and ICAM-1 Genetic Polymorphisms on Response to Direct Antiviral Treatment Among HCV Infected Patients.
    Elsheredy AG; Almaeen AH; Ghazy AA; Helaly GF; Amer I; Ghazy HA; Haydara T
    Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1328-1335. PubMed ID: 32368983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients.
    Chuang JY; Yang SS; Lu YT; Hsieh YY; Chen CY; Chang SC; Chang CS; Yeh HZ; Kao JH
    Dig Liver Dis; 2009 Jun; 41(6):424-30. PubMed ID: 19004675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.
    Hlaing NK; Banerjee D; Mitrani R; Arker SH; Win KS; Tun NL; Thant Z; Win KM; Reddy KR
    World J Gastroenterol; 2016 Nov; 22(43):9613-9622. PubMed ID: 27920482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
    Konishi H; Motomura T; Matsumoto Y; Harimoto N; Ikegami T; Yoshizumi T; Soejima Y; Shirabe K; Fukuhara T; Maehara Y
    J Viral Hepat; 2014 Jun; 21(6):397-404. PubMed ID: 24750545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Myxovirus Resistance Gene Promoter Polymorphism with Response to Combined Interferon Treatment and Progression of Liver Disease in Chronic HCV Egyptian Patients.
    Bader El Din NG; Salum GM; Anany MA; Ibrahim MK; Dawood RM; Zayed N; El Abd YS; El-Shenawy R; El Awady MK
    J Interferon Cytokine Res; 2015 Aug; 35(8):641-8. PubMed ID: 25868067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
    Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
    Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variation in NOS2A is associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese Chinese.
    Lim YP; Peng CY; Liao WL; Hung DZ; Tien N; Chen CY; Chang SY; Chang CY; Tsai FJ; Wan L
    J Med Virol; 2013 Jul; 85(7):1206-14. PubMed ID: 23918539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.
    Mueller T; Mas-Marques A; Sarrazin C; Wiese M; Halangk J; Witt H; Ahlenstiel G; Spengler U; Goebel U; Wiedenmann B; Schreier E; Berg T
    J Hepatol; 2004 Oct; 41(4):652-8. PubMed ID: 15464247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
    BMC Gastroenterol; 2017 Apr; 17(1):54. PubMed ID: 28415985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study.
    Chang ML; Lin YS; Chang MY; Hsu CL; Chien RN; Fann CS
    Virulence; 2021 Dec; 12(1):270-280. PubMed ID: 33446046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.